top of page

The SOLID Team

Mette2.jpg

Mette Trauelsen, PhD
CEO

Mette Trauelsen, CEO and co-founder of SOLID Therapeutics, has a background with a MSc in Biotechnology and a PhD in GPCR Pharmacology with focus on metabolite sensing GPCRs. 3+ years postdoctoral experience working on drug discovery within oncology including being head of Pharmacology and Cancer Biology at SOLID Therapeutics (previously Warburg Oncology).

Patrick.jpg

Patrick Johnson, BSc
Head of Medicinal Chemistry

Patrick S. Johnson graduated from Imperial college London and is a highly motivated project leader, with 35 years of experience, engaged in both synthetic chemistry and medicinal chemistry design within global pharmaceutical companies (Pfizer and Leo Pharma). Involved in research across numerous biological mechanisms and pathways, resulting in being named as inventor or author on >30 patents and papers across a wide range of target classes. Most recent focus being on oral delivery within the beyond rule of 5 property space particularly with drug modalities that hijack the ubiquitin proteasome pathway (TPD/PROTACs).

Eliana.jpg

Eliana Goncalves Alves, PhD
Industrial Postdoc

ORCID_iD.svg.png

Eliana Goncalves Alves has a background in Immunology from her work in the Rheumatology Department of the Medical University of Vienna and in Cancer Biology from her PhD work at Hospital Sant Joan de Déu in Barcelona. During her PhD and Posdoc at the University of Copenhagen she studied the role of GPCRs in several in vivo and in vitro cancer models and its potential pharmacological target. During her career she has been part of several national and international collaborative projects and she is a graduate from the CaSR Biomedicine  Marie-Skłodowska Curie European Training Network.

Sofie.jpg

Sofie Liljewall, M.Sc.Eng
Industrial PhD student

Sofie Liljewall holds a Master of Science in Engineering degree from Lund University. She did her master within Molecular Biotechnology and conducted her master thesis project in the lab of Thue W. Schwartz under the supervision of Mette Trauelsen. Since graduating Sofie has worked as a research assistant for SOLID Tx, driving the companies in vitro and ex vivo activities.

Hagop Youssoufian, MD, Adj. Prof.
Advisor, Preclinical Development

Hagop Youssoufian MD, Adjunct Professor of Medicine at Brown University; co-founder of SOLID Therapeutics. Expert clinical oncologist; Elected member of American Society of Clinical Investigation; Strategic advisor for several biotech/pharma companies and Funds; Extensive R&D leadership experience as CMO or President of R&D; Led the development and approval of 10 cancer drugs; Played major roles in the exit and acquisition of biotech companies, including ImClone by Eli Lilly.

STINE.jpg

Stine Falsig Pedersen, Prof., PhD
Advisor, Cell Biology and TME

Stine Falsig Pedersen, Ph.D., Professor of Cell Biology and Physiology at UCPH; co-founder of SOLID Therapeutics, renowned cell biology researcher focusing on cancer biology; opinion leader in control of tumor microenvironment; member of the Royal Danish Academy of Science and Letters and previously president of the International Society for Cancer Metabolism.

Thomas.jpg

Thomas M. Frimurer, Assoc. Prof., PhD
Advisor, Computational Chemistry

Thomas M. Frimurer PhD, Associate Professor and director of Computational Chemistry Platform at CBMR; co-founder of SOLID Therapeutics, an expert and innovator within structure-based chemical design with 25-year industrial (Novo Nordisk) and biotech (7TM Pharma – Head of Computational Chemistry) experience; serial biotech entrepreneur including co-founder of Ankrin Therapeutics (cancer/DNA repair); holder of multiple patents in drug discovery.

The SOLID Board of Directors

John.jpg

John Haurum, MD, Dphil
Chairman

John Haurum MD, D.Phil.; co-founder of SOLID Therapeutics, Non-executive Director in various European biotech companies (CatalYm, Adcendo, Synklino, Neophore, Storm, Agomab); was CEO of F-star in Cambridge, UK (2012-2018), building a successful company initiating several clinical trials in oncology and generated more than €200M in non-dilutive revenue; Previously VP of Research at ImClone, NY (2010-2012), and before that CSO and cofounder of Symphogen A/S, Denmark.

Thue.jpg

Thue W. Schwartz, Prof., MD, DMSci
Member of the Board, Advisor, GPCR Pharmacology

Thue W. Schwartz, MD, D.M.Sc., Professor in Molecular Pharmacology and co-founder of NNF Center for Basic Metabolic Research (CBMR) at UCPH; co-founder of SOLID Therapeutics; 35-year experience in GPCR structural biology, ligand binding and receptor activation, last decade focusing on metabolite sensing GPCRs; member of Royal Danish Academy of Science and Letters; 25 year Biotech experience including co-founding of first DK biotech-focused VC fund, BBU-I financing e.g. Profound, GenMab, and Zealand. Co-founder of own biotech companies, e.g. 7TM Pharma and Embark Biotech.

Claus Haase.jpg

Claus Haase, PhD
Member of the Board

Claus Haase PhD, co-founder of SOLID Therapeutics, currently SVP, Head of Biologic Drug Design at Symphogen. Has 15+ years' experience in immunological drug discovery at pharmaceutical companies including several leadership positions at Novo Nordisk, Ferring and LEO Pharma.

BII_1.png

Matthias Wulf
Board Observer, BII

Description

Søren_D_Juhl.jpeg

Søren D. Juhl, MSc Biotech, MSc BA
Board Observer, EIFO

Søren D. Juhl, MSc in Biotech and MSc in BA. Representing the Danish Export & Investment Fund (EIFO); a one-point entry for Danish-anchored companies seeking loans and venture financing. The portfolio of the life science investment team encompasses over 30 companies specializing in biotech, digital health and medtech across multiple stages. Has an interdisciplinary background in engineering and business. Have held various positions in the Danish life science ecosystem (Niras, Aquaporin, Novo Nordisk, Ambu) prior to joining the investment team in EIFO.

bottom of page